Lee Ainslie Arvinas, Inc. Call Options Transaction History
Maverick Capital LTD
- $5.08 Billion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ARVN
# of Institutions
246Shares Held
62.5MCall Options Held
2.65MPut Options Held
1.1M-
Vanguard Group Inc Valley Forge, PA8.36MShares$54.4 Million0.0% of portfolio
-
Black Rock Inc. New York, NY6.26MShares$40.7 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il3.88MShares$25.2 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.83MShares$24.9 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY3.33MShares$21.7 Million0.38% of portfolio
About ARVINAS, INC.
- Ticker ARVN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,205,300
- Market Cap $346M
- Description
- Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...